Pink SheetThe US Centers for Medicare and Medicaid Services’ proposal to select certain fixed-dose drug combinations for Medicare price negotiation is “impermissibly” at odds with the US Food and Drug Administr
ScripRegardless of the political turmoil at home and abroad this year, global biopharma companies’ and investors’ interest in South Korea appears to be intact or even growing, amid continued solid R&D
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis Inks Four-Year Proteome Resear
ScripThe US Food and Drug Administration’s decision to remove Risk Evaluation and Mitigation Strategies (REMS) requirements for CAR-T cell therapies and streamline patient monitoring will likely expand the